Schonnemann, K. R.3; Mortensen, M. B.4; Kroll Bjerregaard, Jon3; Fristrup, C.4; Pfeiffer, P.3
1 Oncology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU2 Surgery, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU3 Oncology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU4 Surgery, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU
Purpose. The purpose was to examine characteristics, treatment and outcome in an unselected, prospectively registered complete population of patients with gastro-oesophageal adenocarcinoma cancer (GEA). Methods. All cases diagnosed with GEA between 2008 and 2009 in the Region of Southern Denmark (pop: 1 200 000) were registered. Patient characteristics, including performance status, stage and therapy, were retrieved from patient charts and used to compare sub-groups of patients. Results. Three hundred and thirty patients were registered as having GEA. Patients were divided into three clinical subgroups based on initial treatment option: group 1: patients with resectable GEA (n = 113); group 2: patients receiving first-line therapy (n = 107); group 3: patients receiving no tumour-directed therapy (n = 110). Median overall survival (95% CI) in the three groups was 36 months (25-not reached), 7.1 months (7-9) and 2.4 months (2-3), respectively. Seven percent of patients participated in clinical trials. Conclusion. Among patients not amendable to resection, around 30% are candidates for three-drug combination chemotherapy. Age > 65 years was found not to be a poor prognostic factor for survival, giving the possibility of treating elderly patients in the future. Many patients (approx. 30%), however, never received cancer-directed therapy. In order to improve survival in the entire population, it is important that future trials also focus on this group of patients.
Acta Oncologica, 2014, Vol 53, Issue 3, p. 385-391
GASTRIC-CANCER PERIOPERATIVE CHEMOTHERAPY 1ST-LINE THERAPY PHASE-III POPULATION SURVIVAL SURGERY ESOPHAGEAL ADENOCARCINOMA CAPECITABINE